Partner David Berl has been recognized by Law360 as a “Life Sciences MVP” for 2022.  Each year, Law360 recognizes a small number of MVPs in each practice area, identifying attorneys who “have distinguished themselves from their peers by securing hard-earned successes in high-stakes litigation, complex global matters and record-breaking deals.”

David, who co-chairs the firm’s Patent Litigation practice, spoke to Law360 about his accomplishments over the past year, including his work on multiple trials and successful appeals before the U.S. Court of Appeals for the Federal Circuit.  David notes that “he's driven by the strategic aspects of the life sciences law practice and that he's fascinated by the underlying science,” adding that “he does his best to always know a given case inside and out, both in regard to the court record and the scientific aspects.” 

David focuses his practice principally in the biotechnology, pharmaceutical, and energy fields.  He has served as lead counsel in numerous biotechnology and pharmaceutical patent trials, in appellate proceedings in the Federal Circuit, and in inter partes review proceedings before the PTO.  He regularly serves as lead counsel to major corporations in significant patent litigations.

Click here to read David’s Law360 profile.